Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy

Boye, Kristina S.; Matza, Louis S.; Stewart, Katie D.; Jordan, James O.; Biricolti, Giovanni; Santo, Silvia Del; Pérez-Nieves, Magaly; Federici, Marco Orsini; Gentilella, R.; Losi, Serena; Norrbacka, Kirsi

doi:10.1080/13696998.2019.1609482

Cited by 19 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 88%

“…These findings are consistent with those from four previous studies comparing the dulaglutide device to either the semaglutide device or the very similar liraglutide device, despite differences in study methods. 36,37,43,50 The dulaglutide device was preferred over the comparator device by 83.1% to 94.5% of participants in three studies, in which patients learned about the devices from written descriptions accompanied by illustrations or videos. 36,37,43 In another study with a group of 58 patients who had used the dulaglutide and liraglutide devices, patients were asked to compare their current device to their previous treatment, which was discontinued over a year earlier on average.…”

Section: Discussionmentioning

confidence: 99%

“…10,[39][40][41][42] The dulaglutide and semaglutide injection devices have been compared in a previous study in which preferences were based on descriptions of the devices with images from the device instructions for use, rather than actual experience of using the devices. 43 The primary objective of the current study was to examine preference between the dulaglutide and semaglutide injection devices after participants had been trained to inject with both devices and then used them to administer injections into an injection pad. The gated secondary objective was to compare the two devices with respect to overall ease of use.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Matza

Boye

Stewart

et al. 2019

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

Aim When selecting treatments for type 2 diabetes (T2D), it is important to consider not only efficacy and safety, but also other treatment attributes that have an impact on patient preference. The objective of this study was to examine preference between injection devices used for two weekly GLP‐1 receptor agonists. Materials and Methods The PREFER study was an open‐label, multicentre, randomized, crossover study assessing patient preference for dulaglutide and semaglutide injection devices among injection‐naïve patients receiving oral medication for type 2 diabetes. After being trained to use each device, participants performed all steps of injection preparation and administered mock injections into an injection pad. Time‐to‐train (TTT) for each device was assessed in a subset. Results There were 310 evaluable participants (48.4% female; mean age, 60.0 years; 78 participants in the TTT subgroup). More participants preferred the dulaglutide device than the semaglutide device (84.2% vs. 12.3%; P < 0.0001). More participants perceived the dulaglutide device to have greater ease of use (86.8% vs. 6.8%; P < 0.0001). After preparing and using the devices, more participants were willing to use the dulaglutide device (93.5%) than the semaglutide device (45.8%). Training participants to use the dulaglutide device required less time than the semaglutide device (3.38 vs. 8.14 minutes; P < 0.0001). Conclusions Participants with type 2 diabetes preferred the dulaglutide injection device to the semaglutide injection device. If patients prefer a device, they may be more willing to use the medication, which could result in better health outcomes. Furthermore, a shorter training time for injection devices may be helpful in busy clinical practice settings.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Matza

Boye

Stewart

et al. 2019

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…These tend to be reflected in quality of life assessments. 25 Finally, there is the issue of cost, which will obviously vary in different health care systems. Where the prices of the long-acting GLP-1RAs are equivalent, then health technology analyses are largely driven by HbA1c and weight and reflect differences in efficacy.…”

Section: Discussionmentioning

confidence: 99%

<p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</p>

Chudleigh¹,

Platts²,

Bain³

2020

DMSO

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW "long-acting" GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.

show abstract

“…Although PROs for patients taking dulaglutide and liraglutide have previously been reported in clinical trials, real-world evidence is limited [11][12][13][14][15][16][17]. We studied the use of these GLMs in a single prospective observational study, thereby addressing the need for additional real-world evidence.…”

Section: Digital Features Introductionmentioning

confidence: 99%

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

Boye

Sapin²,

García‐Pérez³

et al. 2020

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

Introduction: Although patient-reported outcome (PRO) measures provide important information beyond clinical data, studies that assess the PROs of type 2 diabetes mellitus (T2DM) patients initiating injectable glucose-lowering medications in routine clinical practice are limited. We describe the perspectives of patients based on a diversified panel of generic and disease-specific PRO measures at the time of enrollment (baseline) in the TROPHIES study. Methods: TROPHIES is a 24-month prospective observational study performed in France, Germany, and Italy in patients with T2DM who initiated their first injectable glucose-lowering medication with once-weekly dulaglutide or once-daily liraglutide. To better understand the perspectives of these patients regarding their overall health, treatment satisfaction, and quality of life and work, the patients' responses to the following questionnaires were collected at baseline before they initiated treatment with dulaglutide or liraglutide:

show abstract

Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy

Cited by 19 publications

References 38 publications

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

<p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</p>

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

Contact Info

Product

Resources

About